Status:
Ready to upload
Record number:
2185
Adverse Occurrence type:
MPHO Type:
Estimated frequency:
Most recent risk assessment for renal cell carcinoma (Council of Europe, 2022):
To provide valid histological staging, complete tumour resection (R0) is required for acceptance of all organs; additionally, tumour-free margins are a prerequisite for transplant of the affected kidney. Paraffin section is superior to frozen section for the assessment of such biopsies. The contralateral kidney should always be examined for synchronous RCC (5 % of patients). RCC < 1 cm (stage T1a AJCC 8th ed) and WHO/ISUP grade I/II (Fuhrman grade I/II) can be considered minimal-risk for transmission; RCC 1-4 cm (stage T1a AJCC 8th ed) and WHO/ISUP grade I/II (Fuhrman grade I/II) are considered low-risk; RCC > 4-7 cm (stage T1b AJCC 8th ed) and WHO/ISUP grade I/II (Fuhrman grade I/II) are considered intermediate-risk; RCC > 7 cm (stage T2 AJCC 8th ed) and WHO/ISUP grade I/II (Fuhrman grade I/II) are considered high-risk; RCC with extension beyond the kidney (stages T3/T4 AJCC 8th ed) is considered a contraindication to transplant; All RCC with WHO/ISUP grade III/IV (Fuhrman grade III/IV) are considered high-risk for transmission; Contralateral kidneys and other organs that are uninvolved in carcinoma are considered to represent minimal risk for transplantation when the RCC in the involved kidney is 4 cm or less and WHO/ISUP grade I-II. In all cases, follow-up surveillance is desirable.
RCC in the donor history: The transmission risk of treated RCC depends on the histological type of tumour and its recurrence-free follow-up period. In general, in the first 5 years after initial diagnosis, risk categories correspond to those stated above (RCC diagnosed during donor procurement) if there is no suspicion of tumour recurrence in the donor. After this time, the risk of advanced stages may decrease.
Time to detection:
In two living donors pre-transplant evaluation of the donors revealed a renal mass of 0.9 cm and 0.7 cm respectively. It was decided to perform laprascopic donor neprectomy and resction of the tumor at the bench. After enucleation histopathological examination confirmed renal cell carcinoma with low grade pT1a, R0 (clear cell RCC and papillary RCC). During >3 yrs. follow up no signs of malignancy was obsered in the two recipients under strict follow up. Immunosuppression was done by using mTOR inhibitor.
Alerting signals, symptoms, evidence of occurrence:
Standard CT-Imaging pre living donor TX
Demonstration of imputability or root cause:
N/A
Groups audience:
Keywords:
References:
Suggest new keywords:
Malignancy
Single Center Series
Living donor
Kidney transplant
Kidney recipient
Histopathological examination
Renal cell carcinoma
Therapy discussed
Suggest references:
Lim SY, Kim MG, Park KT, Jung CW. Experiences of renal transplants from donors with renal cell carcinoma after ex vivo partial nephrectomy. Ann Surg Treat Res. 2017 May;92(5):361-364. doi: 10.4174/astr.2017.92.5.361. Epub 2017 Apr 27. PMID: 28480182; PMCID: PMC5416927.
Note:
Uploaded MN 5/8/22
first review CLFF 5/24/22 See also Record 2180
Sdecond review DN Aug 10 2024.
Expert comments for publication:
The authors conclude: "kidneys with small incidental tumors can be transplanted in selected patients, after careful pathological examination and appropriate surgical excision. These patients might benefit from using an mTOR inhibitor-based regimen for immunosuppression because of its antitumoral effects in renal cell carcinoma. Despite the advantages of using kidneys after removal of the tumor, the potential risk of recurrent disease is a concern when kidneys with renal cell carcinoma are used for transplantation. Hence, the recipients should maintain routine follow-up for imaging studies to ensure that there is no tumor recurrence or to exclude metastasis.". The experience is very limited and the recipient has to be informed.
See also Notify Record 2180